# A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

> **NCT01316601** · PHASE2 · COMPLETED · sponsor: **Gerhard Rogler** · enrollment: 3 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** QAX567

## Key facts

- **NCT ID:** NCT01316601
- **Lead sponsor:** Gerhard Rogler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2015-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316601, "A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01316601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*